Related Experiment Video
Updated: Jan 14, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
Published on: March 6, 2018
Review of Current Guidelines and Innovations in Benign Prostatic Hyperplasia Evaluation and Management
Jaspreet S Sandhu1, Felix Cheung2
1Department of Surgery/Urology, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, New York, NY 10065, USA.
Abstract:
This comprehensive review highlights recent advancements in the evaluation and management of benign prostatic hyperplasia (BPH), emphasizing updates from the 2023 American Urologic Association Guidelines. It outlines an individualized, algorithmic approach to diagnosis using clinical, imaging with emerging roles for artificial intelligence and machine learning. Surgical options span from minimally invasive treatments like prostatic urethral lift, water vapor injection therapy, and temporary implanted prostatic devices to definitive therapies like holmium laser enucleation of the prostate, photoselective vaporization of the prostate, robotic waterjet treatment, and robotic prostatectomy. Future directions involve novel therapeutics, precision medicine, and cost-effectiveness in optimizing BPH management.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Urinary Tract Calculi III: Medical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

